Document is current
Any future updates will be listed below
-
Authors
Chai, Peiyuan
Kheiri, Sina https://orcid.org/0000-0002-9934-4297
Kuo, Andrew
Shah, Jessica https://orcid.org/0000-0002-0760-4232
Kageler, Lauren
Ge, Ruiqi
Perr, Jonathan https://orcid.org/0000-0002-0014-2565
Porat, Jennifer https://orcid.org/0000-0002-1709-4635
Lebedenko, Charlotta G.
Dias, Joao M. L.
Yankova, Eliza https://orcid.org/0000-0003-2913-0012
Rai, Sandeep K.
Watkins, Christopher P.
Hristov, Petar
Tzelepis, Konstantinos https://orcid.org/0000-0002-4865-7648
Hla, Timothy https://orcid.org/0000-0001-8355-4065
Raman, Ritu
Calo, Eliezer https://orcid.org/0000-0002-3006-2742
Esko, Jeffrey D. https://orcid.org/0000-0001-8322-1834
Flynn, Ryan A. https://orcid.org/0000-0001-5013-0442
- License Information
-
More Information
Article History
Received: 16 December 2023
Accepted: 15 December 2025
First Online: 28 January 2026
Competing interests
: R.A.F. is a stockholder of ORNA Therapeutics; and a board of directors member and stockholder of Blue Planet Systems. K.T. is a shareholder of and has received research funding from Storm Therapeutics. R.A.F., E.C. and P.C. have filed a patent related to HS-targeting domains. J.D.E. is a co-founder of TEGA Therapeutics. J.D.E. and The Regents of the University of California have licensed a University invention to and have an equity interest in TEGA Therapeutics. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. R.A.F. and P.C. have filed a patent related to the use of RNase for the modulation of growth factor activity. R.A.F., P.C. and E.C. have filed a patent related to the development and use of RNA-binding mutant growth factors. The other authors declare no competing interests.
